Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials.

OBJECTIVE To determine agreement between spectral-domain (SD) and time-domain (TD) optical coherence tomography (OCT) image assessments by certified readers in eyes treated for neovascular age-related macular degeneration (AMD). DESIGN Cross-sectional study within the Comparison of AMD Treatments Trials (CATT). PARTICIPANTS During year 2 of CATT, 1213 pairs of SD OCT and TD OCT scans were compared from a subset of 384 eyes. METHODS Masked readers independently graded OCT scans for presence of intraretinal fluid (IRF), subretinal fluid (SRF), and sub-retinal pigment epithelium (RPE) fluid and performed manual measurements of retinal, SRF, and subretinal tissue complex thicknesses at the foveal center. MAIN OUTCOME MEASURES Presence of fluid was evaluated with percent agreement, κ coefficients with 95% confidence intervals (CIs), and McNemar tests. Thickness measurements were evaluated with mean difference (Δ) ±95% limits of agreement and intraclass correlation coefficients (ICCs) with 95% CIs. RESULTS Between SD OCT and TD OCT, agreement on presence of any fluid was 82% (κ = 0.46; 95% CI, 0.40-0.52), with 5% more SD OCT scans demonstrating fluid (P<0.001). Agreement on presence of SRF was 87% and sub-RPE fluid was 80%, with more SD OCT scans demonstrating fluid (both P < 0.001). Agreement on IRF was 73% (κ = 0.47; 95% CI, 0.42-0.52), with 6% more TD OCT scans demonstrating fluid (P < 0.001). Between SD OCT and TD OCT, mean thickness of the retina was Δ = 5±67 μm, SRF was Δ = 1.5±35 μm, and subretinal tissue complex was Δ = 5±86 μm. Thickness measurements were reproducible for retina (ICC = 0.84; 95% CI, 0.83-0.86), SRF (ICC = 0.88; 95% CI, 0.86-0.89), and subretinal tissue complex (ICC = 0.91; 95% CI, 0.89-0.92), with ≤25-μm difference in these measurements in 71%, 94%, and 61% of paired scans, respectively. CONCLUSIONS Agreement on fluid presence and manual thickness measurements between paired scans from each OCT modality was moderate, providing a reasonable basis to compare CATT results with future SD OCT-based trials. Fluid was detected 5% more frequently with SD OCT, which may increase frequency of fluid-based treatment. Lower-resolution and artifactual interpretation of dark areas as cystoid edema may explain the greater frequency of IRF detected with TD OCT.

[1]  Sumit Sharma,et al.  Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. , 2009, Ophthalmology.

[2]  Christian Ahlers,et al.  Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy. , 2011, Investigative ophthalmology & visual science.

[3]  Ian C. Han,et al.  Comparison of spectral- and time-domain optical coherence tomography for retinal thickness measurements in healthy and diseased eyes. , 2009, American journal of ophthalmology.

[4]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[5]  C. Toth,et al.  Reproducibility of Optical Coherence Tomography Image Grading During the Comparisons of Age-Related Macular Degeneration Treatments Trials (CATT) , 2012 .

[6]  Changhuei Yang,et al.  Sensitivity advantage of swept source and Fourier domain optical coherence tomography. , 2003, Optics express.

[7]  Glenn J Jaffe,et al.  Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. , 2013, Ophthalmology.

[8]  Glenn J Jaffe,et al.  Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. , 2013, Ophthalmology.

[9]  Robert N Weinreb,et al.  Comparison of macular thickness measurements between time domain and spectral domain optical coherence tomography. , 2008, Investigative ophthalmology & visual science.

[10]  A. Feinstein,et al.  High agreement but low kappa: I. The problems of two paradoxes. , 1990, Journal of clinical epidemiology.

[11]  G. Ying,et al.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.

[12]  Joseph A Izatt,et al.  CORRELATION OF PATHOLOGIC FEATURES IN SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY WITH CONVENTIONAL RETINAL STUDIES , 2008, Retina.

[13]  A. Hendrickson,et al.  A qualitative and quantitative analysis of the human fovea during development , 1986, Vision Research.

[14]  Christian Simader,et al.  Evaluation of optical coherence tomography findings in age-related macular degeneration: a reproducibility study of two independent reading centres , 2008, British Journal of Ophthalmology.

[15]  G. Ying,et al.  Petaloid Macular Edema and Outcomes in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) , 2015 .

[16]  C. Toth,et al.  Optical coherence tomography reader agreement in neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.

[17]  A. Alm,et al.  Is quantitative spectral‐domain superior to time‐domain optical coherence tomography (OCT) in eyes with age‐related macular degeneration? , 2012, Acta ophthalmologica.

[18]  J. Duker,et al.  Ultrahigh-resolution, high-speed, Fourier domain optical coherence tomography and methods for dispersion compensation. , 2004, Optics express.

[19]  B. Bouma,et al.  Improved signal-to-noise ratio in spectral-domain compared with time-domain optical coherence tomography. , 2003, Optics letters.

[20]  G G Koch,et al.  A general methodology for the analysis of experiments with repeated measurement of categorical data. , 1977, Biometrics.

[21]  Sandra S Stinnett,et al.  Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. , 2012, Ophthalmology.

[22]  D. Browning Interobserver variability in optical coherence tomography for macular edema. , 2004, American journal of ophthalmology.

[23]  J. Caprioli,et al.  Optical coherence tomography to detect and manage retinal disease and glaucoma. , 2004, American journal of ophthalmology.

[24]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[25]  Joan W. Miller,et al.  Reproducibility of retinal thickness measurements on normal and pathologic eyes by different optical coherence tomography instruments. , 2010, American journal of ophthalmology.

[26]  Barry Cense,et al.  Spectral domain optical coherence tomography: ultra-high speed, ultra-high resolution ophthalmic imaging. , 2005, Archives of ophthalmology.

[27]  M. Shahidi,et al.  Quantitative thickness measurement of retinal layers imaged by optical coherence tomography. , 2005, American journal of ophthalmology.

[28]  J. Duker,et al.  Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. , 1996, Ophthalmology.

[29]  F. Folgar,et al.  Assessment of retinal morphology with spectral and time domain OCT in the phase III trials of enzymatic vitreolysis. , 2012, Investigative ophthalmology & visual science.

[30]  Susanne Binder,et al.  Repeatability and reproducibility of retinal thickness measurements by optical coherence tomography in age-related macular degeneration. , 2010, Ophthalmology.